NEW YORK (GenomeWeb News) – Nuclea Biotechnologies today said that it raised $4.2 million in its Series D round. The Pittsfield, Mass.-based company added that it plans to close the $5 million round on May 31.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: factors influencing retrotransposon integration sites, and more.
A bioethicist argues for the responsible use of germline gene editing.
Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.
Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.